Notice of Intent to Sole Source Cost-Per-Result-Reportable Automated Hematology Analyzer System for Naval Medical Center Portsmouth
Closed Pre-Solicitation Posted
- Solicitation number
- 12374114
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Place of performance
- Portsmouth, Virginia 23708, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency intends to award a sole-source firm fixed-price contract to Sysmex America, Inc. for a Cost-Per-Result-Reportable Automated Hematology Analyzer System at Naval Medical Center Portsmouth, with responses to this notice due June 11, 2026. The sole-source justification rests on Sysmex's XN-9100-202 analyzer and RU20 reagent dilution unit, which utilize fluorescent flow cytometry technology to analyze RNA and DNA content and intracellular structures—capabilities unavailable from competing vendors and essential for superior white blood cell differentiation, improved detection of immature and abnormal cells including blasts and atypical lymphocytes, and reduced manual smear review workload. The RU20 reagent dilution unit is unique to Sysmex and reduces inventory, storage, and diluent changes, addressing NMCP's space constraints pending laboratory renovation. Market research evaluated Sysmex, Beckman Coulter, Siemens Healthineers, and Abbott Diagnostics; only Sysmex meets all clinical and operational requirements.
Place of performance is Naval Medical Center Portsmouth, Virginia, with normal operations Monday through Friday 0700–1700 except federal holidays; emergency services outside these hours may be required. The contract runs from July 1, 2026 through June 30, 2027 (base year), with four one-year option periods and one optional six-month extension through December 31, 2031. The system encompasses equipment, reagents, maintenance, consumables, 24/7 technical support, and laboratory information system integration (HL7/TCP-IP connectivity with MHS Genesis) at no additional cost. Annual volume is 190,000 reportable CBC tests. Total estimated value is $1,891,450. Sysmex holds a Federal Supply Schedule contract V797D-40235 valid through August 31, 2029. Respondents must present clear and convincing evidence that competition would be advantageous, cost-effective, and not mission-hindering.
Notice text
The Government hereby submits a notice of intent to award a sole source Firm-Fixed-Price contract to Sysmex America, INC. for commercial-off-the-shelf (COTS) Cost-Per-Result-Reportable (CPRR) Automated Hematology Analyzer System. The contract will consist of a base year and four (4) option years, and one (1) Optional six (6) Month Option; the period of performance for the base year is 01July2026 - 30June2027. Sysmex America, INC.'s XN-9100-202 is the only source available that utilizes fluorescent flow cytometry, which analyzes RNA and DNA content and intracellular cellular structures rather than relying solely on impedance and light scatter. This technology provides superior differentiation of white blood cell populations and improves identification of immature and abnormal cells, including blasts, atypical lymphocytes, and immature granulocytes. These capabilities support higher flagging accuracy, reduced manual smear reviews, and earlier clinical decision-making, directly impacting patient care quality and safety. Another feature is the RU 20 reagent dilution unit that has reduced diluent changes, inventory and storage. The RU is unique to Sysmex and offered by no other vendor. These features not only reduce the manual workload on minimal undermanned laboratory staff and minimal storage area needed, but increases, accuracy, efficiency, and readiness for regulatory audits within space constraints due to delays in renovation for NMCP’s laboratory. The total estimated value is $1,891,450.00. Market research has determined that Sysmex America, INC. has a strategically sourced Federal Supply Schedule contract V797D-40235 for CPRR Automated Hematology Analyzer System which is valid through 31August2029. Responses to this notice must demonstrate clear and convincing evidence that competition would be advantageous to the Government, would not be cost or time prohibitive, and would not hinder the mission objective of Naval Medical Center Portsmouth. The determination not to compete this proposed contract action is solely within the discretion of the Government. Information received will normally be considered for the purposes of determining whether to conduct a competitive procurement. The Government will not be responsible for any costs incurred by responding to this notice. This is not a request for quote or proposals. Questions or comments to this Notice of Intent should be directed to Contract Specialist, Lisa Wilk at lisa.c.wilk.civ@health.mil and Contract Officer, Carol Uebelacker at carol.e.uebelacker.civ@health.mil. Please indicate in the subject of your email: Notice of Intent Question Submission 12374114.
Files
| File | Type | Posted |
|---|---|---|
| NOI SAM Posting JA Sysmex Hematology Analyzer RFO Part 6 and Class Deviation 2026-O0017 Redacted.pdf | ||
| Draft SOW for NOI CPRR Hematology.docx | DOCX document |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity